Additionally, it has been confirmed that silencing of the cytokine receptor TNFRSF13B might serve as a new therapeutic target for triple-negative breast cancer, as it could result in significant death in breast cancer cell lines. The gene discussed is TNFRSF13B; the disease is triple-negative breast carcinoma.